JNK和P38MAPK信号通路与大肠癌关系的研究进展(3)
[10]Ouyang X,Jessen WJ,Al-Ahmadie H,et al.Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer[J].Cancer Res,2008,68(7):2132-2144.
[11]Hui L,Bakiri L,Stepniak E,et al.p38alpha:a suppressor of cell proliferation and tumorigenesis[J].Cell Cycle,2007,6(20):2429-2433.
[12]Thornton TM,Rincon M.Non-classical p38 map kinase functions:cell cycle checkpoints and survival[J].Int J Biol Sci,2009,5(1):44-51.
[13]Thornton TM,Pedraza-Alva G,Deng B,et al.Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation[J].Science,2008,320(5876):667-670.
[14]Ordonez-Moran P,Larriba MJ,Palmer HG,et al.RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression,phenotype,and Wnt pathway in colon cancer cells[J].J Cell Biol,2008,183(4):697-710.
[15]Gout S,Morin C,Houle F,et al.Death receptor-3,a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation[J].Cancer Res,2006,66(18):9117-9124.
[16]Mantovani A,Allavena P,Sica A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444.
[17]Reinhardt HC,Aslanian AS,Lees JA,et al.p53-deficient cells rely on ATM-and ATR- mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage[J].Cancer Cell,2007,11(2):175-189.
[18]Vaidya AA,Sharma MB,Kale VP.Suppression of p38-stress kinase sensitizes quiescent leukemic cells to anti-mitotic drugs by inducing proliferative responses in them[J].Cancer Biol Ther,2008,7(8):1232-1240.
[19]Bogoyevitch MA,Arthur PG.Inhibitors of c-Jun N-terminal kinases:JuNK no more[J].Biochim Biophys Acta,2008,1784(1):76-93.
[20]Stebbins JL,De SK,Machleidt T,et al.Identification of a new JNK inhibitor targeting the JNK-JIP interaction site[J].Proc Natl Acad Sci USA,2008,105(43):16809-16813.
[21]陈洪生，周淑筠，刘明.肠梗阻支架在大肠癌低位梗阻中的应用[J].中国医学创新，2010，7(4):86-87., 百拇医药(储诚森 吴佩)
[11]Hui L,Bakiri L,Stepniak E,et al.p38alpha:a suppressor of cell proliferation and tumorigenesis[J].Cell Cycle,2007,6(20):2429-2433.
[12]Thornton TM,Rincon M.Non-classical p38 map kinase functions:cell cycle checkpoints and survival[J].Int J Biol Sci,2009,5(1):44-51.
[13]Thornton TM,Pedraza-Alva G,Deng B,et al.Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation[J].Science,2008,320(5876):667-670.
[14]Ordonez-Moran P,Larriba MJ,Palmer HG,et al.RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression,phenotype,and Wnt pathway in colon cancer cells[J].J Cell Biol,2008,183(4):697-710.
[15]Gout S,Morin C,Houle F,et al.Death receptor-3,a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation[J].Cancer Res,2006,66(18):9117-9124.
[16]Mantovani A,Allavena P,Sica A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444.
[17]Reinhardt HC,Aslanian AS,Lees JA,et al.p53-deficient cells rely on ATM-and ATR- mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage[J].Cancer Cell,2007,11(2):175-189.
[18]Vaidya AA,Sharma MB,Kale VP.Suppression of p38-stress kinase sensitizes quiescent leukemic cells to anti-mitotic drugs by inducing proliferative responses in them[J].Cancer Biol Ther,2008,7(8):1232-1240.
[19]Bogoyevitch MA,Arthur PG.Inhibitors of c-Jun N-terminal kinases:JuNK no more[J].Biochim Biophys Acta,2008,1784(1):76-93.
[20]Stebbins JL,De SK,Machleidt T,et al.Identification of a new JNK inhibitor targeting the JNK-JIP interaction site[J].Proc Natl Acad Sci USA,2008,105(43):16809-16813.
[21]陈洪生，周淑筠，刘明.肠梗阻支架在大肠癌低位梗阻中的应用[J].中国医学创新，2010，7(4):86-87., 百拇医药(储诚森 吴佩)